John Odle
Podiatrist · Jasper, ALNPI 1902984834
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Organogenesis Inc. accounts for 68.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $443 and has fallen 79.4% since, to $91 in 2025.
Across 44 payments — averaging $32.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$979
- Musculoskeletal Transplant Foundation Inc.$122
- Boston Scientific$106
- Stryker$91
- KCI USA, Inc.$52
- Nevro Corp.$20
- plus $58 from 5 others
What the payments were for
- Speaking & faculty fees$604%
- Food & beverage$1,36896%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 26 | $979 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $122 |
| Boston Scientific | 6 | $106 |
| Stryker | 2 | $91 |
| KCI USA, Inc. | 2 | $52 |
| Nevro Corp. | 1 | $20 |
| Heron Therapeutics, Inc. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $12 |
| Triad Life Sciences Inc. | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$222
- Puraply Antimicrobial$125
How this compares
$1,428 in reported general payments places this provider in the 55th percentile of 59 podiatrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 13 | $4,797 |
| Terbinafine Hcl | 38 | $337 |
| Cephalexin | 36 | $263 |
| Mupirocin | 25 | $211 |
| Methylprednisolone | 16 | $162 |
| Meloxicam | 11 | $80 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Jasper
- Michael HamesFlorence$100K
- James MorganMobile$21K
- John RobersonBirmingham$10K
- Kyle MaukBirmingham$10K
- Johnnie AlstonMontgomery$9K
- Heidi ChristieMontgomery$7K
- Brent HaverstockBirmingham$7K
- David LindeBirmingham$6K
- Robert OcampoCullman$5K
- Jamie ClecklerBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.